Literature DB >> 8922357

Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study.

P J Bingley1.   

Abstract

Many studies have examined the role of age, islet cell antibodies (ICAs), insulin autoantibodies (IAAs), and first-phase insulin responses (FPIRs) to an intravenous glucose tolerance test (IVGTT) as markers of risk of progression to IDDM, but a large data set is required for the analysis of the interactions between these markers. The Islet Cell Antibody Register Users Study (ICARUS) register includes 456 first-degree relatives with ICA levels > or = 5 JDF U confirmed in a reference laboratory, 108 of whom have progressed to IDDM in the course of prospective follow-up. Analysis of this data set confirmed the importance of the loss of FPIR, high ICA titer, coexistence of IAA, and young age in enhancing the risk of progression to the disease. The influence of any given marker of risk is modified by the presence or absence of the other markers. Cox regression analysis performed in a subset of 217 subjects for whom IVGTT, ICA, and IAA data were available showed that risk was most strongly associated with loss of FPIR; IAA and ICA titer contributed equally to the model, while age was also an independent risk determinant.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922357     DOI: 10.2337/diab.45.12.1720

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Autoantibodies and high-risk HLA susceptibility markers in first-degree relatives of Brazilian patients with type 1 diabetes mellitus: a progression to disease based study.

Authors:  L I Alves; E Davini; M R Correia; R T Fukui; R F Santos; M R Cunha; D M Rocha; W M G Volpini; M E R Silva
Journal:  J Clin Immunol       Date:  2012-03-09       Impact factor: 8.317

2.  Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives.

Authors:  P Achenbach; K Warncke; J Reiter; A J K Williams; A G Ziegler; P J Bingley; E Bonifacio
Journal:  Diabetologia       Date:  2006-09-26       Impact factor: 10.122

3.  Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).

Authors: 
Journal:  Diabetologia       Date:  2003-02-27       Impact factor: 10.122

4.  Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes.

Authors:  I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-10-07       Impact factor: 10.122

5.  Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.

Authors:  Petra M Pöllänen; Johanna Lempainen; Antti-Pekka Laine; Jorma Toppari; Riitta Veijola; Paula Vähäsalo; Jorma Ilonen; Heli Siljander; Mikael Knip
Journal:  Diabetologia       Date:  2017-03-31       Impact factor: 10.122

6.  Kidney function, β-cell function and glucose tolerance in older men.

Authors:  Ting Jia; Ulf Risérus; Hong Xu; Bengt Lindholm; Johan Ärnlöv; Per Sjögren; Tommy Cederholm; Tobias E Larsson; Talat Alp Ikizler; Juan J Carrero
Journal:  J Clin Endocrinol Metab       Date:  2014-11-27       Impact factor: 5.958

Review 7.  Prediabetes in children: natural history, diagnosis, and preventive strategies.

Authors:  Petri Kulmala
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Prediction of type 1 diabetes in the general population.

Authors:  Mikael Knip; Sari Korhonen; Petri Kulmala; Riitta Veijola; Antti Reunanen; Olli T Raitakari; Jorma Viikari; Hans K Akerblom
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 19.112

9.  Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk.

Authors:  P J Bingley; E A M Gale
Journal:  Diabetologia       Date:  2006-03-03       Impact factor: 10.122

10.  Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population.

Authors:  Heli T A Siljander; Satu Simell; Anne Hekkala; Jyrki Lähde; Tuula Simell; Paula Vähäsalo; Riitta Veijola; Jorma Ilonen; Olli Simell; Mikael Knip
Journal:  Diabetes       Date:  2009-09-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.